Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2013

Summary of Significant Accounting Policies [Abstract]

Schedule of ResponseDX Accounts Receivable

ResponseDX^® accounts receivable as of December 31, 2012 and March 31, 2013, consisted of the following:

	December 31, 2012			March 31, 2013
				(Unaudited)
Net Medicare receivable	$	890,936		$	1,449,049
Net Private Payor receivable		2,924,412			2,951,765
		3,815,348			4,400,814
Allowance for doubtful accounts		(991,990	)		(1,048,864	)
Total	$	2,823,358		$	3,351,950

Schedule of Estimated Useful Lives of Property and Equipment

Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the double declining balance and straight-line methods over the estimated useful lives of the assets. The Company has determined the estimated useful lives of its property and equipment, as follows:

Laboratory equipment	5 to 7 years
Furniture and Equipment	3 to 7 years
Leasehold Improvements	Shorter of the useful life (5 to 7 years) or the lease term

Schedule of ResponseDX Revenue

The following details ResponseDX^® revenue for the three months ended March 31, 2012 and 2013:

	Three Months
	Ended March 31,
	(Unaudited)
	2012		2013
Net Medicare revenue	$	1,460,318	$	1,344,215
Private Payor revenue		1,485,643		1,838,283
Other		5,841		-
Net ResponseDX ® revenue	$	2,951,802	$	3,182,498

Schedule of Revenue Sources that Account for Greater than 10 Percent of Total Revenue

Revenue sources that account for greater than 10 percent of total revenue are provided below.

	Three Months Ended March 31,
	2012					2013
	(Unaudited)					(Unaudited)
	Revenue		Percent of Total Revenue			Revenue		Percent of Total Revenue
Abbott Molecular, Inc.	$	32,466		1	%	$	910,182		15	%
GlaxoSmithKline LLC and GlaxoSmithKline Biologicals S.A.	$	719,087		18	%	$	1,356,384		23	%
Medicare, net of contractual allowances	$	1,460,318		37	%	$	1,376,900		23	%

Schedule of Customers that Account for Greater than 10 Percent of Accounts Receivable

Customers that account for greater than 10 percent of gross accounts receivable are provided below.

	As of December 31, 2012					As of March 31, 2013
	( Unaudited )					( Unaudited )
	Receivable Balance		Percent of Total Receivables			Receivable Balance		Percent of Total Receivables
Abbott Molecular, Inc.	$	377,296		5.9	%	$	697,622		10.5	%
GlaxoSmithKline LLC and GlaxoSmithKline Biologicals S.A.	$	1,691,144		26.6	%	$	712,477		10.8	%
Medicare, net of contractual allowances	$	890,936		14.0	%	$	1,449,049		22.9	%